DDInter1266 DDInter1678
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after its potent antitumor and immunosuppressive activities were later discovered, it was extensively investigated as an immunosuppressive and antitumour agent. Its primary mechanism of action is the inhibition of the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that regulates cell growth, proliferation, and survival. mTOR is an important therapeutic target for various diseases, as it was shown to regulate longevity and maintain normal glucose homeostasis. Targeting mTOR received more attention especially in cancer, as mTOR signalling pathways are constitutively activated in many types of human cancer. Sirolimus was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants. In November 2000, the drug was recognized by the European Agency as an alternative to calcineurin antagonists for maintenance therapy with corticosteroids. In May 2015, the FDA approved sirolimus for the treatment of patients with lymphangioleiomyomatosis. In November 2021, albumin-bound sirolimus for intravenous injection was approved by the FDA for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumour (PEComa). Sirolimus was also investigated in other cancers such as skin cancer, Kaposi’s Sarcoma, cutaneous T-cell lymphomas, and tuberous sclerosis. The topical formulation of sirolimus, marketed as HYFTOR, was approved by the FDA in April 2022: this marks the first topical treatment approved in the US for facial angiofibroma associated with tuberous sclerosis complex.
Naproxen {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Sirolimus
Naproxen {u} (Compound) causes {v} (Side Effect) Glycosuria
Glycosuria {u} (Side Effect) is caused by {v} (Compound) Sirolimus
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Naproxen {u} (Compound) resembles {v} (Compound) Ibuprofen
Ibuprofen {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Naproxen {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Temsirolimus
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Naproxen {u} (Compound) causes {v} (Side Effect) Glycosuria
Glycosuria {u} (Side Effect) is caused by {v} (Compound) Tacrolimus
Tacrolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Naproxen {u} (Compound) causes {v} (Side Effect) Menstrual disorder
Menstrual disorder {u} (Side Effect) is caused by {v} (Compound) Lansoprazole
Lansoprazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Naproxen {u} (Compound) resembles {v} (Compound) Indomethacin
Indomethacin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Sirolimus
Naproxen {u} (Compound) resembles {v} (Compound) Nabumetone
Nabumetone {u} (Compound) downregulates {v} (Gene) PIK3CA
PIK3CA {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Naproxen {u} (Compound) resembles {v} (Compound) Suprofen
Suprofen {u} (Compound) resembles {v} (Compound) Bromfenac
Bromfenac {u} may lead to a major life threatening interaction when taken with {v} Sirolimus
Naproxen (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Sirolimus (Compound)
Naproxen (Compound) causes Glycosuria (Side Effect) and Glycosuria (Side Effect) is caused by Sirolimus (Compound)
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Sirolimus
Naproxen (Compound) resembles Ibuprofen (Compound) and Ibuprofen may lead to a major life threatening interaction when taken with Sirolimus
Naproxen (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Temsirolimus (Compound) and Temsirolimus (Compound) resembles Sirolimus (Compound)
Naproxen (Compound) causes Glycosuria (Side Effect) and Glycosuria (Side Effect) is caused by Tacrolimus (Compound) and Tacrolimus (Compound) resembles Sirolimus (Compound)
Naproxen (Compound) causes Menstrual disorder (Side Effect) and Menstrual disorder (Side Effect) is caused by Lansoprazole (Compound) and Lansoprazole may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus
Naproxen (Compound) resembles Indomethacin (Compound) and Indomethacin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sirolimus (Compound)
Naproxen (Compound) resembles Nabumetone (Compound) and Nabumetone (Compound) downregulates PIK3CA (Gene) and PIK3CA (Gene) is upregulated by Sirolimus (Compound)
Naproxen (Compound) resembles Suprofen (Compound) and Suprofen (Compound) resembles Bromfenac (Compound) and Bromfenac may lead to a major life threatening interaction when taken with Sirolimus